Sub-Q Ig Therapy is a Convenient Treatment for Primary Immunodeficiency (PI)

Discover the world of Sub-Q Ig self-administration

Vivaglobin^® Sub-Q is infused on a weekly basis “subcutaneously” into the fatty tissue just below the skin—in the thighs, upper arms, stomach, or hips—anywhere you can “pinch an inch.”

Multiple Injection Graph

Self-administered Sub-Q Ig therapy:

Can increase freedom and flexibility in your treatments
Can be easy to learn
Can provide you with opportunity to infuse your therapy at home and even when you travel

New freedom and new responsibilities
To gain the freedom and flexibility of Sub-Q Ig, you will need to take charge and own your therapy. First you will undergo special Sub-Q Ig training to ensure that you can infuse your Ig on your own.

Learning Sub-Q Ig self-administration can be simple¹
You can download materials from this Web site that can help reinforce your healthcare professional’s instructions, and help you understand the self-infusion process. You will also gain practical and hands-on information from healthcare professionals like your doctor and nurse.

Click to view a PDF from the National Institute of Health on Giving a Subcutaneous Injection.

Infusing Vivaglobin^® at home
Learning how to infuse Vivaglobin^® weekly at home is simple, and your healthcare professional can begin to teach you this process during your first infusion.^1,2 If your doctor decides that Vivaglobin^® is right for you, it’s very important that you learn proper administration techniques.

How to Self-Administer Vivaglobin^®: A Step-by-Step Guide. Click here for the PDF.

References:

Nicolay U, Kiessling P, Berger M, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26:65-72.
Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies - a prospective, multi-national study. J Clin Immunol. 2006;26:177-185.

Next: About Vivaglobin^®

Important Safety Information

Immune Globulin Subcutaneous (Human), Vivaglobin^®, is a prescription treatment for patients with primary immunodeficiency (PI).

Immune globulin products, such as Vivaglobin^®, should not be taken if you have a history of anaphylactic or severe systemic response to immune globulin (Ig) preparations. If you suspect you are having a severe reaction to Vivaglobin^®, discontinue treatment immediately and inform your doctor.

Vivaglobin^® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In clinical trials, the most frequent adverse event was mild or moderate swelling, redness, and itching at the injection site. Other adverse events included headache, gastrointestinal disorder, fever, nausea, sore throat, and rash. No serious reactions were observed, and reactions tended to decrease substantially with repeated use.

If you are receiving Ig therapy for the first time, are new to Vivaglobin^®, or have not received Ig therapy within the past eight weeks, your healthcare provider should monitor your initial treatment with Vivaglobin^®, as you could experience reactions including fever, chills, nausea, and vomiting. Rarely, these reactions may lead to shock.

Ig administration may impair the effectiveness of virus vaccines, such as measles, mumps and rubella. Consult your doctor if you plan to receive any vaccine.

In clinical studies, Vivaglobin^® has been shown to be safe and well tolerated in pediatric patients, without pediatric-specific dose requirements. Safety and effectiveness were not studied in subjects under 2 years of age.

Please see full Prescribing Information and Patient Product Information.